ctDNA

ctDNA is small fragments of DNA shed into the bloodstream by cancer cells as they grow, die, or turn over. Because these fragments carry the same genetic mutations as the tumor itself, a blood draw can sometimes detect cancer-specific signals without a tissue biopsy. ctDNA is one form of "liquid biopsy" and is increasingly used to monitor how a cancer is responding to treatment.

Origin

The presence of cell-free DNA in human blood was first described by Mandel and Métais in 1948, but the cancer-specific fraction (ctDNA) was not characterized until the 1990s when researchers identified tumor mutations in plasma DNA. Clinical use expanded rapidly in the 2010s with next-generation sequencing, which made it possible to detect very small amounts of mutated DNA among normal background DNA.

Significance in Asbestos Context

For patients with mesothelioma or asbestos-related lung cancer, ctDNA testing can help in several ways: identifying mutations (such as in BAP1, NF2, or EGFR) that may guide treatment choices, tracking whether a tumor is shrinking or growing during chemotherapy or immunotherapy, and detecting recurrence earlier than scans alone. Mesothelioma tends to shed less ctDNA than many other cancers, so results can be limited, but the field is advancing quickly. Patients should ask their oncologist whether ctDNA testing is appropriate for their specific tumor type and stage, and whether results could open the door to clinical trials or targeted therapies. Any ctDNA results become part of the medical record and can support the medical documentation of disease course in a legal claim.

Example Sentence

After two cycles of chemotherapy, her oncologist ordered a ctDNA test to see whether tumor-derived mutations in her bloodstream were decreasing, suggesting the treatment was working.

Related Terms

Liquid Biopsy, Biomarker, BAP1, Mesothelioma, Next-Generation Sequencing, Tumor Mutational Burden

Notes

• Ask your oncologist whether ctDNA or broader molecular profiling (tissue or blood-based) has been done on your tumor. Results may qualify you for targeted therapies or clinical trials.
• If you have mesothelioma, ask specifically about testing for BAP1, NF2, CDKN2A, and MTAP alterations, which can affect prognosis and trial eligibility.
• Keep copies of all molecular and ctDNA reports; these can become important evidence of diagnosis, tumor biology, and treatment response in both medical care and legal claims.
• A negative ctDNA result does not mean cancer is absent. Mesothelioma in particular can shed little DNA into the blood, so imaging and biopsy remain central.
• Insurance coverage for ctDNA testing varies; ask the ordering physician's office to confirm coverage or assist with prior authorization before the blood draw.